Brief: Helix Biopharma successfully out-licenses late stage Biphasix technology
23/12/2016 12:45
Dec 23 (Reuters) - Helix Biopharma Corp HBP.TO :
* Under terms of agreement, Xisle has paid an up-front fee
and agreed to subsequent milestone payments
* Helix Biopharma Corp - Xisle will be responsible for
continued clinical development and subsequent commercialization
of product
* Helix Biopharma Corp successfully out-licenses late stage
Biphasix technology
* Helix Biopharma Corp - signed exclusive out-license
agreement with Xisle Pharma ventures trust for company's
late-stage, Biphasix technology platform
Source text for Eikon: ID:nMKWSQ5j9a
Further company coverage: HBP.TO
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Helix Biopharma
See all newsBrief: Helix Biopharma Reports Q3 Loss Per Share C$0.02
Brief: Helix Biopharma Intends To File Interim Consolidated Financial Statements By July 30
Brief: Helix Biopharma To Divest Remaining Ownership Of Polish Subsidiary
Brief: Helix Biopharma Says Expects To File Interim Disclosure Documents By July 30, 2020
Brief: Helix Biopharma Says L-Dos47 Phase I Lung Cancer Trial Data To Be Released At Asco 2020